Case Study
Acute Lymphoblastic Leukemia
Case Study
LatticePoint provided extensive client support while the internal market access team was being built
Background
- Product was acquired by mid-sized pharma
- Client had received pricing advice prior to LPC involvement
- The product was being sold via EAPs in several markets across Europe prior to receiving EMA approval
LatticePoint Engagement
- LatticePoint pricing strategy identified a commercial pricing increase relative to existing EAP priceWe developed the payer value proposition, global value dossiers and market entry strategy
- Develop launch sequencing to optimize list prices across the EU to minimize reference pricing impact to revenue
- Developed Health Economic models (cost-effectiveness, cost minimization, budget impact)
- Developed and submitted reimbursement dossiers, including:
- Reinforce evidence arguments via systematic literature reviews (SLRs), meta-analyses and indirect comparisons
- Developed Health Economic models (cost-effectiveness, cost minimization, budget impact) tailored for each country